Photo by nci from unsplash
and two had treatment tolerance requiring a change in therapy. In this group (n = 24), the median OS after BV failure was only 3 months, and 2‐year OS was… Click to show full abstract
and two had treatment tolerance requiring a change in therapy. In this group (n = 24), the median OS after BV failure was only 3 months, and 2‐year OS was 30%. Of 6 long‐term (>1 year) survivors, five underwent subsequent SCT (allo n = 3, auto n = 2). One had good response to investigational clinical trial treatment, and one had localized indolent disease. Conclusions: Refractory disease to last therapy and higher sIPI at start of BV were associated with inferior outcomes in ALCL following BV. Further, patients with disease progression after use of BV have a dismal outcome.
Journal Title: Hematological Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!